Kymera COO sells 300 shares after option exercises
Kymera Therapeutics Chief Operating Officer Jeremy G. Chadwick reported a mix of option exercises and a small stock sale.
Rhea-AI Filing Summary
Kymera Therapeutics Chief Operating Officer Jeremy G. Chadwick reported a mix of option exercises and a small stock sale. On April 22, 2026, he exercised stock options for a total of 300 shares of common stock at exercise prices of $43.50 and $30.17 per share, then made an open-market sale of 300 shares at $90.00 per share. After these transactions, he directly held 61,202 shares of Kymera common stock. The filing notes that the transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted in December 2025, indicating they were scheduled in advance rather than timed discretionarily.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and Sale: 300 shares ($15K approx. pre-tax spread)
Exercise and Sale
5 txns
Insider
Chadwick Jeremy G
Role
Chief Operating Officer
Sold
300 shs ($27K)
Approx. gross sale proceeds
$27K
Approx. exercise cost
$12K
Approx. pre-tax spread
$15K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 100 | $0.00 | $0.00 |
| Exercise | Stock Option (Right to Buy) | 200 | $0.00 | $0.00 |
| Exercise | Common Stock | 100 | $30.17 | $3K |
| Exercise | Common Stock | 200 | $43.50 | $9K |
| Sale | Common Stock | 300 | $90.00 | $27K |
Holdings After Transaction:
Stock Option (Right to Buy) — 103,697 contracts (Direct);
Common Stock — 61,202 shares (Direct)
Footnotes (3)
- F1. These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 10, 2025 adopted by the reporting person.
- F2. The shares underlying this stock option shall vest in thirty-six (36) equal monthly installments following March 3, 2025, subject to the reporting person's continued employment through each vesting date.
- F3. The shares underlying this stock option shall vest in thirty-six (36) equal monthly installments following March 1, 2024, subject to the reporting person's continued employment through each vesting date.
Key Figures
Shares sold: 300 shares
Sale price: $90.00 per share
Options exercised (43.50): 200 shares at $43.50
+5 more
8 metrics
Shares sold
300 shares
Open-market sale of common stock at $90.00 on April 22, 2026
Sale price
$90.00 per share
Price for 300 Kymera common shares sold by COO
Options exercised (43.50)
200 shares at $43.50
Stock option exercise into common stock on April 22, 2026
Options exercised (30.17)
100 shares at $30.17
Additional stock option exercise into common stock
Post-transaction holdings
61,202 shares
Common stock directly held after transactions
Option expiration (43.50 strike)
February 28, 2034
Expiration date for $43.50 stock option grant
Option expiration (30.17 strike)
March 2, 2035
Expiration date for $30.17 stock option grant
Net share direction
-300 shares
Net buy/sell shares across reported transactions
Key Terms
Rule 10b5-1 trading plan, Stock Option (Right to Buy), exercise or conversion of derivative security, open-market sale, +1 more
5 terms
Rule 10b5-1 trading plan financial
"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 10, 2025"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy) with underlying security title Common Stock"
exercise or conversion of derivative security financial
"transaction_code_description: Exercise or conversion of derivative security"
open-market sale financial
"transaction_action: open-market sale for 300.0000 shares of Common Stock"
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
vest in thirty-six (36) equal monthly installments financial
"The shares underlying this stock option shall vest in thirty-six (36) equal monthly installments"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Kymera (KYMR) COO Jeremy Chadwick do in this Form 4 filing?
Kymera COO Jeremy G. Chadwick exercised stock options for 300 shares and sold 300 common shares at $90 each. All trades occurred on April 22, 2026 under a pre-arranged Rule 10b5-1 trading plan adopted in December 2025.
Were Kymera (KYMR) COO Jeremy Chadwick’s trades part of a Rule 10b5-1 plan?
Yes. The filing states that the transactions were executed under a Rule 10b5-1 trading plan dated December 10, 2025. Such plans allow insiders to schedule trades in advance, reducing concerns that the timing reflects undisclosed company information.
What stock options did the Kymera (KYMR) COO exercise according to this Form 4?
He exercised two stock option grants: 200 options with a $43.50 exercise price expiring February 28, 2034, and 100 options with a $30.17 exercise price expiring March 2, 2035. Both options relate to Kymera common stock as the underlying security.
How do the Kymera (KYMR) COO’s option grants vest over time?
The filing notes that one option grant vests in 36 equal monthly installments after March 3, 2025, and another vests in 36 equal monthly installments after March 1, 2024. Vesting is contingent on his continued employment through each monthly vesting date.
AI-generated analysis. How Rhea-AI works. Not financial advice.
